尤瑞克林联合依达拉奉治疗急性脑梗死临床研究

Clinical research of urinary kallidinogenase united edaravone treating acute cerebral infarction

目的:探讨尤瑞克林联合依达拉奉治疗急性脑梗死的临床效果。方法:83例急性脑梗死患者随机分为观察组43例和对照组40例。对照组在对症治疗基础上给予依达拉奉治疗;观察组在对照组治疗基础上加以尤瑞克林治疗,两组疗程均为14 d。分别于治疗前、治疗后14 d进行NIHSS并评定临床疗效。结果:观察组与对照组治疗前、治疗后14 d NIHSS评分分别比较,差异有统计学意义(P<0.05);治疗组与对照组治疗后比较,差异有统计学意义(P<0.05)。两组显效率及总有效率分别比较,差异有统计学意义(P<0.05)。结论:尤瑞克林联合依达拉奉治疗急性脑梗死,能有效改善患者神经功能缺失,安全、有效。

Objective： To investigate clinical effects of urinary kallidinogenase united edaravone treatment of acute cerebral infarction.Methods： 83 patients with acute cerebral infarction were randomly divided into observation group 43 cases and the control group of 40 patients.The control group were given edaravone on the basis of the symptomatic treatment;observation group were gaven urinary kallidinogenase treatment on base of control group,both two groups treated for 14 d.before treatment and 14 d after treatment to NIHSS evaluation of clinical efficacy.Results： The combination of the control group before treatment,14 d after the NIHSS scores were compared,the difference were statistically significant（P0.05）;the treatment group compared with the control group after treatment,the difference was statistically significant（P0.05）.The two groups were,respectively,efficiency and total efficiency,the difference was statistically significant（P0.05）.Conclusion： Urinary kallidinogenase united edaravone for acute cerebral infarction,can improve neurological function in patients,and it is safe and effective.